(Reuters) – Johnson & Johnson said on Friday it plans to conduct a late-stage study of its investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.
The drugmaker already has a mid-stage HIV vaccine study underway in five southern African countries.
There are currently no vaccines for HIV, a virus that weakens the body’s immune system.
Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila
Our Standards:The Thomson Reuters Trust Principles.
Source: Reuters.com
